Ciprofloxacin, Levofloxacin, and Moxifloxacin: A Clinical Comparison of Fluoroquinolone Safety and Use

The fluoroquinolones are a class of antibiotics with broad-spectrum activity against many gram-negative and gram-positive pathogens, providing an appealing option for many types of infections. The most commonly utilized systemic fluoroquinolones in clinical practice include ciprofloxacin, levofloxacin, and moxifloxacin; ciprofloxacin was first approved by the US Food and Drug Administration (FDA) in 1987, followed by levofloxacin in 1996 and moxifloxacin in 1999.^1-3

The mechanism of action involves inhibiting bacterial topoisomerase IV and DNA gyrase (which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination.^1-3 Fluoroquinolones target gram-negative organisms by binding to DNA gyrase and gram-positive organisms mainly by binding to topoisomerase IV. They have activity against most susceptible isolates of gram-positive bacteria, including but not limited to Enterococcus faecalis, Staphylococcus aureus (methicillin-susceptible and -resistant S aureus), Streptococcus pneumoniae, and Streptococcus pyogenes, as well as gram-negative bacteria, including but not limited to Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, and Legionella species.^1-3

They are commonly utilized for nosocomial and community-acquired pneumonia, skin and skin structure infections, and complicated intra-abdominal infections because of excellent oral bioavailability and tissue penetration, optimal once- or twice-daily dosing, and convenient intravenous-to-oral conversion options, offering seemingly appealing options for both providers and patients. However, safety and resistance concerns have emerged since the initial approval of these agents.

Fluoroquinolone Safety and Resistance Concerns

Several differences exist between each fluoroquinolone. Moxifloxacin should not be used for urinary tract infections because of an inability to achieve high concentrations in the urine and primary liver metabolism.² Only ciprofloxacin and levofloxacin are indicated for the treatment of chronic bacterial prostatitis and urinary tract infections.^1,3 Unlike levofloxacin and ciprofloxacin, moxifloxacin does not require dose adjustments for renal impairment.^1-3 Ciprofloxacin is commonly dosed twice daily in patients with normal renal function, whereas levofloxacin and moxifloxacin offer convenient once-daily dosing.^1-3

The fluoroquinolones have broad coverage against many gram-negative and gram-positive organisms. Unlike moxifloxacin, ciprofloxacin and levofloxacin provide coverage against susceptible strains of Pseudomonas aeruginosa.^1-3 Ciprofloxacin has also been used for infectious diarrhea caused by E coli, Campylobacter jejuni, and Shigella.¹ Moxifloxacin and levofloxacin often have greater activity against S pneumoniae compared with ciprofloxacin.⁴ Levofloxacin generally offers improved gram-positive activity compared with ciprofloxacin, whereas moxifloxacin has improved gram-positive, atypical, and anaerobic coverage compared with ciprofloxacin and levofloxacin.⁴

Antibiotic Resistance

Resistance to fluoroquinolones occurs primarily by mutation in DNA gyrase or topoisomerase IV genes, decreased outer membrane permeability, or drug efflux.² Antibiotic overuse has contributed to antibiotic resistance in the fluoroquinolone class, which limits their utility in infections, particularly where long-term oral therapy and excellent tissue penetration are optimal, such as prostatitis and bone and joint infections.⁵ In these situations, antibiotic selection should be guided by culture and susceptibility, tissue penetration, oral bioavailability, and risk of debilitating adverse reactions from fluoroquinolones. Close monitoring is required, including screening for adverse effects and laboratory abnormalities when utilizing fluoroquinolones long term.

Black Box Warning

All fluoroquinolones include a black box warning for serious and potentially irreversible adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system (CNS) effects.^1-3 They can also exacerbate muscle weakness in patients with myasthenia gravis and should be avoided in these patients.^1-3

These serious and disabling adverse reactions have occurred within hours to weeks after taking fluoroquinolones. Fluoroquinolones should be discontinued in any patients who experience these adverse effects or have experienced them in the past. As with any antibiotics, patients should also be monitored for hypersensitivity reactions and gastrointestinal adverse reactions, including Clostridioides difficile.^1-3 Patients should also be monitored for hepatotoxicity when taking fluoroquinolones.

There is also an increased risk of aortic aneurysm and dissection following the use of fluoroquinolones.^1-3 These antibiotics should be reserved when there are no alternatives in patients with known or greater risk for aortic aneurysms. Quinolones have also been associated with hypo-/hyperglycemia, and blood glucose monitoring is recommended in patients with diabetes. Ciprofloxacin should be avoided with theophylline because of the increased risk of developing CNS adverse reactions.¹ 

Fluoroquinolones should be avoided in patients with known QT prolongation, hypokalemia, and other medications that can prolong the QT interval.^1-3 All oral fluoroquinolones bind with multivalent cations, including multivitamins, antacids, sucralfate, and dairy products, and spacing is recommended because of decreased absorption. Ciprofloxacin should be given 2 hours before or 6 hours after cations.¹ Moxifloxacin should be taken at least 4 hours before or 8 hours after, and levofloxacin should be given at least 2 hours before or after.^2,3

As a class, fluoroquinolones can also enhance the anticoagulant effects of warfarin, and anticoagulation tests should be closely monitored.^1-3 Other pertinent drug interactions can be found in the respective package inserts.

FDA Label Change

Because of these serious and potentially disabling and irreversible adverse effects, the FDA updated safety labeling in 2016 for all systemic fluoroquinolones and advised restricting use for uncomplicated infections.⁶ The label change emphasizes the risk of serious potential adverse effects associated with the antibiotics, outweighing the potential benefits when utilized for uncomplicated infections, defined as acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections.⁶

The FDA recommends reserving the use of fluoroquinolones for patients with no other treatment options when treating these infections.⁶ Examples include instances when a first-line therapy cannot be utilized because of resistance or a contraindication to a first-line therapy, such as antibiotic failure or allergy.

REFERENCES

1. Cipro. Prescribing information. Bayer HealthCare Pharmaceuticals; 2024. https://labeling.bayerhealthcare.com/html/products/pi/Cipro_Tabs_OS_PI.pdf
2. Avalox. Prescribing information. Bayer HealthCare Pharmaceuticals; 2025. https://www.bayer.com/sites/default/files/avalox-tab-smpc-apr-2024.pdf
3. Levofloxacin. Prescribing information. Hospira Inc; 2024. https://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=4996
4. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003;9(1):1-9. doi:10.3201/eid0901.020277
5. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician. 2002;65(3):455-465. https://www.aafp.org/afp/2002/0201/p455
6. FDA approves safety labeling changes for fluoroquinolones. US Food and Drug Administration. Updated July 26, 2016. Accessed May 26, 2026. https://www.fda.gov/drugs/information-drug-class/fda-approves-safety-labeling-changes-fluoroquinolones